VolitionRx’s (VNRX) Hold Rating Reiterated at Benchmark

Benchmark reiterated their hold rating on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Friday morning,Benzinga reports.

Separately, StockNews.com started coverage on shares of VolitionRx in a research note on Wednesday, November 20th. They issued a “sell” rating on the stock.

VolitionRx Price Performance

NYSE:VNRX opened at $0.70 on Friday. VolitionRx has a one year low of $0.43 and a one year high of $1.23. The company has a market cap of $65.22 million, a PE ratio of -1.95 and a beta of 1.10. The firm’s 50 day simple moving average is $0.69 and its 200 day simple moving average is $0.68.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC lifted its holdings in VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.